相关实验视频

Updated: Sep 17, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

低剂量infigratinib治疗是一种有效的策略,用于治疗低性质质症

Benoit Demuynck¹, Bhavik P Shah², Franck Mayeux¹

¹Université de Paris Cité, Imagine Institute, INSERM UMR 1163, F-75015, Paris, France.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

|June 29, 2025

概括

印菲格拉提尼布在治疗罕见的遗传骨发育不良症 - - 低性质细胞增生症方面表现有前途. 这种纤维细胞生长因子受体3 (FGFR3) 抑制剂在临床前研究中显示出治疗潜力,为改善骨生长提供了希望.

科学领域:

遗传学是一个遗传学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

低性质是一种罕见的遗传骨发育不良症,由FGFR3变异引起,导致不成比例的矮身.
目前没有准确疗法被批准用于低性质形成症.
作为FGFR1-3抑制剂的infigratinib针对FGFR3相关的骨功能障碍的潜在病理生理学.

研究的目的:

评估因菲格拉提尼布在患有下极性质的治疗相关性.
通过in silico,in vitro和in vivo模型来评估infigratinib的疗效.
为了支持用于治疗低性质形成症的infigratinib的临床开发.

主要方法:

在in silico评估因菲格拉提尼布与高性质流失症相关的FGFR3变体的相互作用.
在体外研究以确定infigratinib对FGFR的抑制作用3.
评估infigratinib在小鼠模型中用于改善骨生长的低性质形成症 (Fgfr3N534K/+).

主要成果:

在基分析表明,因菲格拉蒂尼布与相关的FGFR3变异之间存在强烈的相互作用.
在体外实验证实了infigratinib的强烈抑制活性.
在低性质形成症小鼠模型中,infigratinib治疗导致了骨生长的显著改善.

结论:

临床前的数据强烈支持infigratinib在治疗性质疏松症的治疗潜力.
印菲格拉提尼布有效地准了下极性质增生症的分子机制.
这些发现,结合第二阶段形质疏松症数据,需要进一步开发用于形质疏松症的因菲格拉提尼布.

关键词:

在这种情况下,infigratinib 应该被使用.这种疾病叫做Achondroplasia.纤维细胞生长因子受体3 过高质量细胞增生不全症是什么骨发育不良症骨发育不良症

更多相关视频

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Published on: November 14, 2013

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...